Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus anlotinib as second-line treatment for thymic carcinoma
ChiCTR2600131276Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and anlotinib in thymic carcinoma (TC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
camrelizumabanlotinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2600131276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131276.